Asia-Pacific anti-hypertensive therapeutics market to hit $27 billion by 2022, despite low innovation

Report Title: Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 – Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

The market for anti-hypertensive therapeutics across the five Asia-Pacific (APAC) countries of India, China, Australia, South Korea, and Japan, is set to grow from $19.1 billion in 2015 to $27 billion by 2022, at a compound annual growth rate of 5.1%.

Gautam Arora, Analyst for GBI Research, explains: “The anti-hypertensive pipeline consists of 112 pipeline products, most of which are small molecules. The limited presence of other types of molecules in the pipeline suggests that large pharmaceutical companies are refraining from developing novel molecules and are more inclined to focus on patient-compliant combination therapies. It is therefore unlikely that any completely novel molecules will enter the market during the forecast period.

“Prestalia is an example of a recently improved drug that offers an improvement to hypertension therapy. In a Phase III trial it provided a better benefit-to-risk ratio than either treatment alone. The drug was approved by the US FDA in January 2015, and it is marketed by Symplmed. Of the APAC countries covered in the report, however, it is available only in Australia, and it is under development in Japan and South Korea.”

Despite the availability of a large number of blood-pressure-lowering agents, the need remains for safer and more effective anti-hypertensive treatments. Although the APAC market is likely to see steady growth, it will continue to be obstructed by a weak pipeline and low diagnosis and treatment rates. Indeed, the asymptomatic nature of the disease along with a lack of frequent blood pressure checks due to limited affordability and healthcare accessibility in countries such as India and China can limit diagnosis rates.

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

John Carpenter House, John Carpenter Street, London EC4Y 0AN, UK.

This release was published on openPR.